Navigation Links
Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
Date:6/2/2008

trial for ANA773 in cancer patients in February and this study of ANA598 underway, Anadys is now focused on achieving important clinical milestones in both programs."

About ANA598

ANA598 is a highly potent and selective inhibitor of HCV genotypes 1a and 1b NS5b RNA polymerases (IC50 < 1 nM) and of HCV replication in cell culture (EC50 values for genotypes 1b and 1a replicons are 3 and 50 nM, respectively). ANA598 has been well-tolerated in all preclinical studies, including 28-day GLP toxicology studies, and was selected as a development candidate in June 2007.

Clinical Need and Market Opportunity in HCV Infection

Chronic hepatitis C virus (HCV) infection is a serious public health concern affecting approximately 2.7 million people in the United States and approximately 170 million people worldwide. HCV causes inflammation of the liver, which may lead to fibrosis and cirrhosis, liver cancer, and ultimately, liver failure. Cirrhosis of the liver resulting from chronic HCV infection is the leading indication for liver transplantation in the U.S. Due to the asymptomatic nature of HCV infection, it often goes undetected for up to 20 years following initial infection. Each year, 8,000 to 10,000 people in the U.S. die from complications of HCV.

The current standard of care is a combination of pegylated interferon and ribavirin. Inadequate response rates, in particular for patients infected with genotype 1 HCV, along with significant side effects of approved therapy, support the medical need for improved treatment options. It is estimated that fewer than 5% of people with chronic HCV infection living in the U.S. are under treatment today. The majority of infected individuals are unaware of their infection status and the large majority of individuals who know their status do not currently receive drug therapy. There is also a growing number of individuals who have failed interferon-based regimens who may be successfully treated with combi
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2014)... KONG, Nov. 28, 2014 HK$,000Six months endedChange %  30 September ... Cord Blood Storage Service Income , 384,242 , ... , 61,878 , 41,377 , 49.5 ... 2,249 , 6.4 Medical Devices and Accessories Sales ... Chinese Herbal Medicines Sales , 2,917 , 9,219 ...
(Date:11/26/2014)...  Thoratec Corporation (NASDAQ: THOR ), a ... save, support and restore failing hearts, said today it ... On Tuesday, December 2, the company will participate ... Conference.  D. Keith Grossman , President and Chief ... beginning at 11:30 a.m., Eastern Standard Time (8:30 a.m., ...
(Date:11/26/2014)... -- Cohen, Placitella & Roth, PC is investigating potential ... Pharmaceutical Corporation ("Nymox" or "Company") (NASDAQ: ... 2011 through November 2, 2014 ("Class Period").  The ... officers and directors publically disseminated materially false and/or ... 20(a) of the Securities Exchange Act of 1934 ...
Breaking Medicine Technology:Golden Meditech Announces 2014 / 2015 Interim Results 2Golden Meditech Announces 2014 / 2015 Interim Results 3Golden Meditech Announces 2014 / 2015 Interim Results 4Golden Meditech Announces 2014 / 2015 Interim Results 5Golden Meditech Announces 2014 / 2015 Interim Results 6Golden Meditech Announces 2014 / 2015 Interim Results 7Golden Meditech Announces 2014 / 2015 Interim Results 8Thoratec Announces Presentations At Investor Conferences For December 2014 2Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation for Failing to Disclose Material Information 2Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation for Failing to Disclose Material Information 3
... COLUMBIA, Md., Nov. 11, 2010 Celsion Corporation ... drug development company, today announced that the Committee ... Medicines Agency (EMA) has issued a positive opinion ... ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, ...
... Arbor Pharmaceuticals, a specialty pharmaceutical company based in Atlanta, ... financing.  This financing included a $17.5 million investment in ... Signet Healthcare Partners, LLC.  The remainder of the financing ... by several of the investing parties.  Also participating in ...
Cached Medicine Technology:Celsion Receives COMP Recommendation for Orphan Drug Designation in Europe for ThermoDox® to Treat Primary Liver Cancer 2Celsion Receives COMP Recommendation for Orphan Drug Designation in Europe for ThermoDox® to Treat Primary Liver Cancer 3Celsion Receives COMP Recommendation for Orphan Drug Designation in Europe for ThermoDox® to Treat Primary Liver Cancer 4Arbor Pharmaceuticals Completes $34.8 Million Financing 2Arbor Pharmaceuticals Completes $34.8 Million Financing 3
(Date:11/28/2014)... 2014 Mirena lawsuits ( http://www.mirenalawsuit2014.com/ ... New Jersey’s Bergen County Superior Court, where the ... there is quickly approaching 1,300, Bernstein Liebhard LLP ... shows 1,293 lawsuits now pending in the consolidated ... complications resulting from spontaneous migration of the birth ...
(Date:11/28/2014)... Walder, one of South Florida’s top cosmetic dermatologists , ... that is designed to help her patients reduce unwanted fat ... has been praised by patients as being permanent, painless, and ... types of external fat reduction. , “If you can pinch ... According to Dr. Walder, Ultrashape works by targeting subcutaneous fat, ...
(Date:11/28/2014)... Texas (PRWEB) November 28, 2014 Dr. Paul Vitenas, ... will hold a Glitter & Glow Holiday Event for those in ... treatments offered at his practice. Glitter & Glow will take place ... Dr. Vitenas’ new location in the heart of Houston at 4208 ... of holidays and hope that you will come and celebrate the ...
(Date:11/28/2014)... 28, 2014 Secura Consultants, based ... insurance marketing organizations in the country focused on ... protection marketplace. Secura Consultants is proud to offer ... Financial Group, a leading global financial company. , ... With the ownership interest comes the need for ...
(Date:11/28/2014)... Celebration can quickly turn to tragedy if popular turkey ... Over the last decade, more than 141 serious fires ... turkey fryers, according to the U.S. Consumer Product Safety ... who tried to deep fry the turkey indoors, which ... Arthur Sanford, a burn surgeon at Loyola University Health ...
Breaking Medicine News(10 mins):Health News:Nearly 1,300 Mirena Lawsuits Now Filed in Consolidated New Jersey Litigation, Bernstein Liebhard LLP Reports 2Health News:Nearly 1,300 Mirena Lawsuits Now Filed in Consolidated New Jersey Litigation, Bernstein Liebhard LLP Reports 3Health News:Dr. Diane Walder Introduces New Fat Reduction Treatment Called Ultrashape 2Health News:Dr. Diane Walder Introduces New Fat Reduction Treatment Called Ultrashape 3Health News:Cosmetic Surgeon Dr. Paul Vitenas to Host Glitter & Glow Holiday Event 2Health News:Cosmetic Surgeon Dr. Paul Vitenas to Host Glitter & Glow Holiday Event 3Health News:Secura Consultants Offers Complimentary Buy-Sell Agreement Reviews 2Health News:Turkey Fryer Mishaps Can Cause Serious Burns 2
... MONDAY, May 23 (HealthDay News) -- Women who gained 18 or ... three times more likely to develop gestational diabetes during their second ... the study, published in the May 23 online issue of ... to shed six or more pounds between babies cut their risk ...
... primary care specialty of internal medicine has identified common clinical ... care and better use of finite clinical resources. ... activities appears online in the Archives of Internal Medicine ... list of best practices via consensus from actual practitioners, said ...
... 23 (HealthDay News) -- Researchers report that they,ve discovered a ... a finding that might provide insight into how the germ ... About 200 million people around the world are thought ... chronically infected people in the United States. Many don,t know ...
... , NEW YORK, May 23, 2011More than eight of ... believe states should be allowed to implement key provisions ... support, ahead of the timeline outlined in the law. ... more low-income families and creating insurance exchanges with premium ...
... , MONDAY, May 23 (HealthDay News) -- Undercover research ... to provide emergency care to children with private insurance ... Posing as mothers of a fictional 10-year-old boy ... 85 dental practices twice, four weeks apart, to determine ...
... is a reasonably safe and accurate method for the initial ... April issue of the Journal of the American College ... shave biopsies for not providing accurate T (tumor) stage information, ... to determine the impact of shave biopsies on the initial ...
Cached Medicine News:Health News:Losing Baby Weight Cuts Odds of Pregnancy-Linked Diabetes 2Health News:'Top 5' list helps primary care doctors make wiser clinical decisions 2Health News:'Top 5' list helps primary care doctors make wiser clinical decisions 3Health News:Researchers Find Cousin of Hepatitis C Virus in Dogs 2Health News:States should be allowed to implement key health reform law provisions early, experts say 2Health News:States should be allowed to implement key health reform law provisions early, experts say 3Health News:Some Dentists Reluctant to Treat Kids on Medicaid: Study 2Health News:Some Dentists Reluctant to Treat Kids on Medicaid: Study 3Health News:Shave biopsy is a safe and acceptable method for initial evaluation of melanoma 2
1000 L, Bulk Recommended for 500 and 1000 L pipettes....
Inquire...
... way to order tips. Each box contains 1000 ... which contains 200 tips (4 bags of 50 ... of 200 tips per pack. Bulk Packs are ... be opened for quick access to Gilsons Diamond ...
... Finntips have been designed to optimize the ... of our tip products is widely recognized ... range has been extended over the years ... standard and special tips including filter tips, ...
Medicine Products: